engleski

PERFORMANCE OF THE STATSTRIP GLUCOSE HOSPITAL METER IN PATIENTS WITH DIABETIC NEPHROPATHY

Background. Interference of hemoconcentration/hemodilution in point-of care glucose testing is well described and correction algorithms used to overcome this problem have limited effects. StatStrip Hospital Glucose Meter provides unique correction for hematocrit, which is simultaneously measured with glucose on the same strip. Methods. The performance of the point-of-care StatStrip Glucose Hospital Meter was assessed in patients with various stages of diabetic nephropathy, associated with anemia (decreased hematocrit levels). Results were compared to the reference hexokinase procedure on Olympus AU400 analyzer. Results. Total of 74 diabetic patients with confirmed diabetic nephropathy were included in this evaluation [age-range=23–83, median= 62, 5 years ; male/female= 52/22, HbA1c range=4, 5 to 10, 4, median=6, 8%]. Hematocrit levels ranged from 0, 236 – 0, 489 L/L, with 54, 1% results below lower limit of reference intervals, and plasma glucose range was 2, 0-17, 6 mmol/L. Median glucose values were 9, 2 and 9, 0 mmol/L for hexokinase and StatStrip, respectively, with 0, 2 mmol/L absolute bias, which is in accordance with desirable specifications for bias derived from intra- and inter-individual biologic variation (2, 2%). Agreement with the hexokinase method was excellent: y = 0.9318x + 0.06705 (Passing Bablok regression) with no significant deviation from linearity (P>0, 10). In a subgroup of patients with low hematocrit Passing-Bablok regression also showed excellent agreement with the hexokinase method (y = 0.9355x – 0, 01613) with no significant deviation from linearity (P>0, 10). Conclusions. StatStrip Glucose Meter can be used as an accurate and reliable tool for monitoring glucose levels in patients with diabetic nephropathy associated with anemia.

glucose; diabetic nephropathy; hematocrit interference

nije evidentirano